Stock Analysis

Why Investors Shouldn't Be Surprised By Solasto Corporation's (TSE:6197) 29% Share Price Surge

TSE:6197
Source: Shutterstock

Solasto Corporation (TSE:6197) shareholders would be excited to see that the share price has had a great month, posting a 29% gain and recovering from prior weakness. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 16% over that time.

Although its price has surged higher, it's still not a stretch to say that Solasto's price-to-sales (or "P/S") ratio of 0.4x right now seems quite "middle-of-the-road" compared to the Healthcare industry in Japan, where the median P/S ratio is around 0.6x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.

View our latest analysis for Solasto

ps-multiple-vs-industry
TSE:6197 Price to Sales Ratio vs Industry September 4th 2024

What Does Solasto's Recent Performance Look Like?

Recent times haven't been great for Solasto as its revenue has been rising slower than most other companies. One possibility is that the P/S ratio is moderate because investors think this lacklustre revenue performance will turn around. If not, then existing shareholders may be a little nervous about the viability of the share price.

Keen to find out how analysts think Solasto's future stacks up against the industry? In that case, our free report is a great place to start.

Is There Some Revenue Growth Forecasted For Solasto?

There's an inherent assumption that a company should be matching the industry for P/S ratios like Solasto's to be considered reasonable.

If we review the last year of revenue growth, the company posted a worthy increase of 3.3%. The solid recent performance means it was also able to grow revenue by 24% in total over the last three years. So we can start by confirming that the company has actually done a good job of growing revenue over that time.

Looking ahead now, revenue is anticipated to climb by 6.0% per annum during the coming three years according to the five analysts following the company. That's shaping up to be similar to the 5.6% each year growth forecast for the broader industry.

With this information, we can see why Solasto is trading at a fairly similar P/S to the industry. Apparently shareholders are comfortable to simply hold on while the company is keeping a low profile.

What We Can Learn From Solasto's P/S?

Solasto's stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

We've seen that Solasto maintains an adequate P/S seeing as its revenue growth figures match the rest of the industry. Right now shareholders are comfortable with the P/S as they are quite confident future revenue won't throw up any surprises. If all things remain constant, the possibility of a drastic share price movement remains fairly remote.

You always need to take note of risks, for example - Solasto has 2 warning signs we think you should be aware of.

If you're unsure about the strength of Solasto's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.